Bio-Rad Laboratories, Inc. (BIO-B) Stock Analysis
Recovery setup
Healthcare · Medical Devices
Sell if holding. Multiple concerning factors at $306.55: Earnings estimates trending DOWN; Weak overall score: 4.7/10.
Bio-Rad Laboratories develops and sells instruments, reagents, and consumables across Life Science (40% of net sales) and Clinical Diagnostics (60% of net sales), with approximately 60% of net sales from international markets and Europe as the largest region. The company employs... Read more
Sell if holding. Multiple concerning factors at $306.55: Earnings estimates trending DOWN; Weak overall score: 4.7/10. Chart setup: Death cross but MACD improving, RSI 100. Score 4.7/10, moderate confidence.
Passes 7/8 gates (positive momentum, clean insider activity, no SEC red flags, news events none recent, earnings proximity no date, semi cycle peak clear, materials cycle peak clear). Suitability: moderate.
Thesis
Key Metrics
Quality Signals
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers·1 ceiling hit
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Growth below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Analyst Consensus
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Multiple concerning factors at $306.55: Earnings estimates trending DOWN; Weak overall score: 4.7/10. Chart setup: Death cross but MACD improving, RSI 100. Prior stop was $298.91. Score 4.7/10, moderate confidence.
Take-profit target: $349.77 (+15.0% upside). Prior stop was $298.91. Stop-loss: $298.91.
Earnings estimates trending DOWN; Weak overall score: 4.7/10; Expensive valuation.
Bio-Rad Laboratories, Inc. trades at a P/E of 50.5 (forward N/A). TrendMatrix value score: 4.0/10. Verdict: Sell.
10 analysts cover BIO-B with a consensus score of 3.5/5.
What does Bio-Rad Laboratories, Inc. do?Bio-Rad Laboratories develops and sells instruments, reagents, and consumables across Life Science (40% of net sales)...
Bio-Rad Laboratories develops and sells instruments, reagents, and consumables across Life Science (40% of net sales) and Clinical Diagnostics (60% of net sales), with approximately 60% of net sales from international markets and Europe as the largest region. The company employs about 7,450 people in 37 countries and held a $5.7 billion Sartorius AG equity stake at December 31, 2025.